VERU INC. Proceeds from Sale of Productive Assets
VERU INC. (VERU) reported Proceeds from Sale of Productive Assets of $0 for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfProductiveAssets · last filed 2026-08-10
- VERU INC. proceeds from sale of productive assets for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- VERU INC. proceeds from sale of productive assets for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- VERU INC. proceeds from sale of productive assets for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- VERU INC. proceeds from sale of productive assets for the quarter ending 2025-09-30 was $6.13M, a 3049.11% increase year-over-year.
- VERU INC. proceeds from sale of productive assets for fiscal 2025 was $8.28M, a 2618.99% increase from fiscal 2024.
- VERU INC. proceeds from sale of productive assets for fiscal 2024 was $304.54K, a 95.65% decline from fiscal 2023.
- VERU INC. proceeds from sale of productive assets for fiscal 2023 was $7.00M.
| Period end | Proceeds from Sale of Productive Assets 3 month | Proceeds from Sale of Productive Assets 6 month | Proceeds from Sale of Productive Assets 9 month | Proceeds from Sale of Productive Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-10 | $0.00 derived: sum of 2 quarters · filed 2026-08-10 | $0.00 10-Q · filed 2026-08-10 | $6.13M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13 | $0.00 10-Q · filed 2026-05-13 | $6.13M derived: sum of 3 quarters · filed 2026-05-13 | $6.61M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $0.00 10-Q · filed 2026-02-11 | $6.13M derived: sum of 2 quarters · filed 2026-02-11 | $6.61M derived: sum of 3 quarters · filed 2026-08-10 | $7.59M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-09-30 | $6.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-17 | $6.61M derived: sum of 2 quarters · filed 2026-08-10 | $7.59M derived: sum of 3 quarters · filed 2026-08-10 | $8.28M 10-K · filed 2025-12-17 |
| 2025-06-30 | $484.62K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-10 | $1.46M derived: sum of 2 quarters · filed 2026-08-10 | $2.15M 10-Q · filed 2026-08-10 | $2.35M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $974.30K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13 | $1.67M 10-Q · filed 2026-05-13 | $1.86M derived: sum of 3 quarters · filed 2026-05-13 | $1.97M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $695.22K 10-Q · filed 2026-02-11 | $889.75K derived: sum of 2 quarters · filed 2026-02-11 | $999.75K derived: sum of 3 quarters · filed 2026-02-11 | $999.75K derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-09-30 | $194.54K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-17 | $304.54K derived: sum of 2 quarters · filed 2025-12-17 | $304.54K derived: sum of 3 quarters · filed 2025-12-17 | $304.54K 10-K · filed 2025-12-17 |
| 2024-06-30 | $110.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-12 | $110.00K derived: sum of 2 quarters · filed 2025-08-12 | $110.00K 10-Q · filed 2025-08-12 | $1.11M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-08 | $0.00 10-Q · filed 2025-05-08 | $1.00M derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | $0.00 10-Q · filed 2025-02-13 | $1.00M derived: sum of 2 quarters · filed 2025-02-13 | ||
| 2023-09-30 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-16 | $7.00M 10-K · filed 2024-12-16 | ||
| 2023-06-30 | $6.00M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |